RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a 'Sector Perform' rating on Sangamo Therapeutics (NASDAQ:SGMO) and maintained a $2 price target.
March 14, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains a 'Sector Perform' rating and a $2 price target on Sangamo Therapeutics.
The reiteration of the 'Sector Perform' rating and the maintenance of the $2 price target by RBC Capital suggests a neutral outlook on SGMO's stock in the short term. Given that there's no change in the rating or price target, the immediate impact on the stock price is likely to be minimal. However, the reaffirmation of the analyst's stance could provide some stability to the stock, indicating that the analyst's view on the company's prospects remains unchanged.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100